IL2 and breast cancer: Trastuzumab emtansine (T-DM1) consisting of trastuzumab coupled to a cytotoxic agent, emtansine (DM1), and DAB(389)IL-2 (denileukin diftitox, ONTAK) made up of the full-length IL-2 molecule and the catalytic domain of diphtheria toxin have approved by FDA and shown significant efficacy and safety in treating patients with advanced breast cancer and cutaneous T-cell lymphoma, respectively [33, 34].